WEANING OF IMMUNOSUPPRESSION IN LIVER TRANSPLANT RECIPIENTS 12
暂无分享,去创建一个
[1] D. V. van Thiel,et al. Evolution of Liver Transplantation , 2007, Hepatology.
[2] T. Starzl,et al. The lost chord: microchimerism and allograft survival. , 1996, Immunology today.
[3] T. Howard,et al. Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor-specific microchimerism. , 1996, Transplantation.
[4] J. Neuberger,et al. Timing, significance, and prognosis of late acute liver allograft rejection. , 1995, Transplantation.
[5] C. Delaney,et al. Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. , 1995, Transplantation.
[6] A. Demetris,et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. , 1995, The American journal of surgical pathology.
[7] T. Starzl,et al. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. , 1995, Transplantation proceedings.
[8] T. Starzl,et al. Weaning Of Immunosuppression In Long‐Term Liver Transplant Recipients , 1995, Transplantation.
[9] G. Gores,et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection , 1994, Hepatology.
[10] T. Starzl,et al. Murine liver allograft transplantation: Tolerance and donor cell chimerism , 1994, Hepatology.
[11] H. Schlitt,et al. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. , 1994, The New England journal of medicine.
[12] T. Starzl,et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. , 1993, Transplantation proceedings.
[13] T. Starzl,et al. Cell migration and chimerism after whole‐organ transplantation: The basis of graft acceptance , 1993, Hepatology.
[14] T. Starzl,et al. Cell migration, chimerism, and graft acceptance , 1992, The Lancet.
[15] D. V. van Thiel,et al. CONVERSION OF LIVER ALLOGRAFT RECIPIENTS FROM CYCLOSPORINE TO FK506 IMMUNOSUPPRESSIVE THERAPY—A CLINICOPATHOLOGIC STUDY OF 96 PATIENTS , 1992, Transplantation.
[16] R. Wiesner,et al. Severe Ductopenic Rejection Following Liver Transplantation: Incidence, Time of Onset, Risk Factors, Treatment, and Outcome , 1992, Seminars in liver disease.
[17] T. Starzl,et al. Fifteen years of clinical liver transplantation. , 1979, Gastroenterology.
[18] T. Starzl,et al. FK 506 for human liver, kidney, and pancreas transplantation , 1989 .